A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years

Pediatric Infectious Disease Journal

Volumn 35, Issue 9, 2016, Pages 992-998

  Lamberti, Laura M ^a   Ashraf, Sania ^a   Walker, Christa L Fischer ^a   Black, Robert E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

children; global; rotavirus; vaccine

Indexed keywords

ROTAVIRUS VACCINE;

CARIBBEAN; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; EAST ASIAN; HUMAN; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTAVIRUS DIARRHEA; ROTAVIRUS INFECTION; SOUTH AND CENTRAL AMERICA; SOUTH ASIAN; SOUTHEAST ASIA; SYSTEMATIC REVIEW; VACCINATION; AFRICA SOUTH OF THE SAHARA; ASIA; DEVELOPING COUNTRY; INFANT; MORTALITY; NEWBORN; ROTAVIRUS; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; ASIA; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DIARRHEA; HUMANS; INFANT; INFANT, NEWBORN; LATIN AMERICA; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84973101032     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001232     Document Type: Review

References (65)

1. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015; 385: 430-440
2. Fischer Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013; 381: 1405-1416
3. Lanata CF, Fischer-Walker CL, Olascoaga AC, et al. Global causes of diarrheal disease mortality in children 5 years of age: a systematic review PloS One 2013 8 e72788
4. Tate JE, Burton AH, Boschi-Pinto C, et al. WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirusassociated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-Analysis. Lancet Infect Dis. 2012; 12: 136-141
5. Glass RI, Parashar U, Patel M, et al. Rotavirus vaccines: successes and challenges. J Infect. 2014; 68(suppl 1): S9-S18
6. World Health Organization. Rotavirus vaccines. WHO Position Paper. Wkly Epidemiol Rec. 2013; 88: 49-64
7. Fu C, Wang M, Liang J, et al. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine. 2007; 25: 8756-8761
8. Fu C, He Q, Xu J, et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012; 31: 154-158
9. Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. India Rotavirus Vaccine Group. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014; 383: 2136-2143
10. Fischer Walker CL, Black RE. Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. BMC Public Health. 2011; 11(suppl 3): S16
11. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012; 2: CD008521
12. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010; 340: c2825
13. Linhares AC, Velazquez FR, Perez-Schael I, et al. Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008; 371: 1181-1189
14. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362: 289-298
15. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376: 606-614
16. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376: 615-623
17. Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, doubleblind, controlled study. Vaccine. 2009; 27: 5936-5941
18. Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 354: 23-33
19. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007; 370: 1757-1763
20. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009; 301: 2243-2251
21. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis. 2009; 49: 428-431
22. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010; 362: 299-305
23. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr. 2004; 144: 184-190
24. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990; 22: 259-267
25. United Nation Statistics Division. Millennium Development Indicators: World and regional groupings. Available at: http://mdgs.un.org/unsd/mdg/Host. aspx?Content=Data/REgionalGroupings.htm. Accessed November 19, 2014
26. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011
27. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010; 201: 1607-1610
28. Munos MK, Walker CL, Black RE. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. Int J Epidemiol. 2010; 39(suppl 1): i75-i87
29. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2011; 15: e206-e210
30. Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent humanbovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatr Infect Dis J. 2012; 31: 184-188
31. Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum Vaccin Immunother. 2013; 9: 1626-1633
32. Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011; 29: 6335-6341
33. Feikin DR, Laserson KF, Ojwando J, et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine. 2012; 30(suppl 1): A52-A60
34. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine. 2012; 30(suppl 1): A44-A51
35. Armah GE, Kapikian AZ, Vesikari T, et al. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis. 2013; 208: 423-431
36. Castilla J, Beristain X, Martínez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine. 2012; 30: 539-543
37. Martinón-Torres F, Alejandro MB, Collazo LR, et al. ROTACOST Research Team. Effectiveness of rotavirus vaccination in Spain. Hum Vaccin. 2011; 7: 757-761
38. Cotes-Cantillo K, Paternina-Caicedo A, Coronell-Rodríguez W, et al. Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study. Vaccine. 2014; 32: 3035-3040
39. Hanquet G, Ducoffre G, Vergison A, et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine. 2011; 29: 4698-4703
40. Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012; 30: 4552-4557
41. Li RC, Huang T, Li YP, et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Hum Vaccin Immunother. 2014; 10: 11-18
42. Lau YL, Nelson EA, Poon KH, et al. Hong Kong Rotarix Study Group. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine. 2013; 31: 2253-2259
43. Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine. 2012; 30(suppl 1): A36-A43
44. Sow SO, Tapia M, Haidara FC, et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine. 2012; 30(suppl 1): A71-A78
45. Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ. 2013; 346: f3726
46. Justino MC, Araujo EC, Van Doorn LJ, et al. Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children Mem Inst Oswaldo Cruz. 2012; 107: 846-853
47. Mast TC, Khawaja S, Espinoza F, et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr Infect Dis J. 2011; 30: e209-e215
48. Staat MA, Payne DC, Donauer S, et al. New Vaccine Surveillance Network (NVSN). Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011; 128: e267-e275
49. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics. 2013; 132: e25-e33
50. Braeckman T, Van Herck K, Meyer N, et al. RotaBel Study Group. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ. 2012; 345: e4752
51. Gagneur A, Nowak E, Lemaitre T, et al. IVANHOE Investigators. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine. 2011; 29: 3753-3759
52. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq (R) vaccine based on 3 years of surveillance following introduction of a Rotavirus Immunization Program in Finland. Pediatr Infect Dis J. 2013; 32: 1365-1373
53. Snelling T, Andrews R, Kirkwood C, et al. Case-control evaluation of the effectiveness of the G1P [8] human rotavirus vaccine during an outbreak of rotavirus G2P [4] infection in central Australia. Clin Infect Dis. 2011; 52: 191-199
54. Ichihara MY, Rodrigues LC, Teles Santos CA, et al. Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: a case-control study. Vaccine. 2014; 32: 2740-2747
55. Groome MJ, Page N, Cortese MM, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis. 2014; 14: 1096-1104
56. Yen C, Guardado JAA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J. 2011; 30: S6-S10
57. Tregnaghi MW, Abate HJ, Valencia A, et al. Rota-024 Study Group. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J. 2011; 30: e103-e108
58. Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. Int J Infect Dis. 2012; 16: e94-e98
59. Fernandes EG, Sato HK, Leshem E, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations in São Paulo State, Brazil. Vaccine. 2014; 32: 3402-3408
60. Adlhoch C, Hoehne M, Littmann M, et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011. Pediatr Infect Dis J. 2013; 32: e82-e89
61. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children 5 years of age, 2009-2011 Clin Infect Dis 2013 57 13-20
62. Vesikari T, Prymula R, Schuster V, et al. Efficacy and immunogenicity of live-Attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J. 2012; 31: 509-513
63. Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr Infect Dis J. 2011; 30: 396-401
64. Zaman K. Introduction of a live, oral human rotavirus vaccine (Rotarix) in Matlab, Bangladesh. 11th International Rotavirus Symposium. New Delhi, India; 2014
65. PATH. Rotavirus vaccine access and delivery. 2015. Available at: http://sites.path.org/rotavirusvaccine/rotavirus-vaccines/#global-intro. Accessed December 16, 2015